- Sputnik International, 1920
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

China's Sinopharm Developing MRNA COVID-19 Vaccine Against New Variants - Official

© AP Photo / Mark SchiefelbeinA visitor wearing a face mask takes a photo of a model of a coronavirus and boxes for COVID-19 vaccines at a display by Chinese pharmaceutical firm Sinopharm at the China International Fair for Trade in Services (CIFTIS) in Beijing, Saturday, Sept. 5, 2020. With the COVID-19 pandemic largely under control, China's capital on Saturday kicked off one of the first large-scale public events since the start of the coronavirus outbreak, as tens of thousands of attendees were expected to visit displays from nearly 2,000 Chinese and foreign companies showcasing their products and services.
A visitor wearing a face mask takes a photo of a model of a coronavirus and boxes for COVID-19 vaccines at a display by Chinese pharmaceutical firm Sinopharm at the China International Fair for Trade in Services (CIFTIS) in Beijing, Saturday, Sept. 5, 2020. With the COVID-19 pandemic largely under control, China's capital on Saturday kicked off one of the first large-scale public events since the start of the coronavirus outbreak, as tens of thousands of attendees were expected to visit displays from nearly 2,000 Chinese and foreign companies showcasing their products and services. - Sputnik International, 1920, 06.09.2021
Subscribe
International
India
BEIJING (Sputnik) - Chinese pharmaceutical company Sinopharm is working on a second-generation mRNA COVID-19 vaccine against new virus variants, Zhu Jingjin, the secretary of the party committee of a Sinopharm subsidiary, said.
The official from China National Biotec Group told China Central Television in an interview, that Sinopharm had already developed four vaccines including two inactivated, one mRNA vaccine, and one recombinant.
"China National Biotec Group is constantly seeking solutions to the complicated scientific and technical problems, and the research and development of the second-generation vaccine against mutated strains of COVID-19 brought good results," Zhu said.
The secretary highlighted that the mRNA vaccine, developed autonomously by China National Biotec Group, is aimed at fighting new COVID-19 variants.
"We all are looking forward for such second-generation vaccine against mutated COVID-19 strains to enter the market as soon as possible, to help the entire world to cope with the pandemic sooner," the official added.
As for the recombinant vaccine, the secretary said that the company had completed the first two stages of clinical trials, and evaluated the vaccine as one of the world's most advanced, as it had proved to be effective against different COVID-19 strains including the Delta variant.
The inactivated Sinopharm's vaccine remains effective for six months after two shots, according to Zhu, who indicated that it fully complies with the World Health Organization requirements.
China has been conducting a successful COVID-19 vaccination policy. Over 2.1 billion vaccine doses have been administered in the country.
Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала